Please login to the form below

Not currently logged in
Email:
Password:

Shire's Q3 net profit doubles

Net profit for Shire recovers from payment to Acceleron and impairment charges relating to the divestment of Daytrana

Shire has recorded a net profit of $192.9m for the third quarter of 2011 – an increase from 2010 of 100 per cent.

Last year, the Ireland-based pharmaceutical company made $96.3m after being hit by payments to Acceleron Pharma and impairment charges related to the divestment of ADHD treatment Daytrana (methylphenidate).

Discounting the one-off charges, as well as other measures specified by the company, net profit was still up, increasing from $220.3m in 2010 to $244.7m in 2011.

This was bolstered by a strong sales performance, with total revenues for Shire increasing 24 per cent to $1.09bn.

Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

Vyvanse made $199.7m, an increase in sales of 32 per cent, while Adderall XR made $149.9m, an increase of 50 per cent.

Angus Russell, CEO of Shire, said: "The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world.

"Overall, we've increased investment in our R&D programmes by 21 per cent compared to Q3 2010, and still generated good earnings growth and strong cashflows."

31st October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

COVID-19: the race to find a vaccine
How biopharma is working to bring an end to the pandemic...
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Global product lead George Kirk hails the triumph of selumetinib, which has just won FDA approval...
ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...

Infographics